Skip to main content

MODELOS MURINOS DERIVADOS DE CELULAS PRIMARIAS DE PACIENTES CON LINFOMA CUTANEO DE CÉLULAS T PARA EL DISEÑO DE TERAPIAS PERSONALIZADAS

PI21/00390

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (FIMIM)
Execution centre INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (IMIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

High-throughput RNA sequencing of the T cell receptor alpha and beta chains for simultaneous clonality and biological analyses in Sezary syndrome

  • Blanco, Gonzalo|||0000-0001-6557-3764
  • López Aventín, Daniel|||0000-0001-5097-5621
  • Pujol Vallverdú, Ramón M.|||0000-0002-5622-6055
  • Gómez-Llonín, Andrea|||0000-0002-7470-6730
  • Puiggros, Anna|||0000-0001-9627-4978
  • López-Sánchez, Manuela|||0000-0002-5094-0266
  • Estrach, Teresa|||0000-0002-4601-2811
  • Garcia Muret, Maria Pilar|||0000-0003-1714-5815
  • Lopez-Lerma, Ingrid|||0000-0002-7690-8926
  • Servitje, Octavio|||0000-0002-9910-9617
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Muro, Manuel|||0000-0001-9987-0994
  • Espinet Solà, Blanca|||0000-0002-4294-8145
  • Rabionet, Raquel|||0000-0001-5006-8140
  • Gallardo, Fernando|||0000-0002-8996-3828
Previous investigations pointed out a role for antigen stimulation in Sezary syndrome (SS). High-throughput sequencing of the T cell receptor (TR) offers several applications beyond diagnostic purposes, including the study of T cell pathogenesis. We performed high-throughput RNA sequencing of the TR alpha (TRA) and beta (TRB) genes focusing on the complementarity-determining region 3 (CDR3) in 11 SS and one erythrodermic mycosis fungoides (MF) patients. Five psoriasis patients were employed as controls. Peripheral blood CD4 + cells were isolated and RNA sequenced (HiSeq2500). High-resolution HLA typing was performed in neoplastic patients. Highly expanded predominant TRA and TRB CDR3 were only found in SS patients (median frequency: 94.4% and 93.7%). No remarkable CDR3 expansions were observed in psoriasis patients (median frequency of predominant TRA and TRB CDR3: 0.87% and 0.69%, p < 0.001 compared to SS). CDR3 almost identical to the predominant were identified within each SS patient and were exponentially correlated with frequencies of the predominant CDR3 (R 2 = 0.918, p < 0.001). Forty-six different CDR3 were shared between SS patients displaying HLA similarities, including predominant TRA and TRB CDR3 in one patient that were found in other three patients. Additionally, 351 antigen matches were detected (Cytomegalovirus, Epstein-Barr, Influenza virus, and self-antigens), and the predominant CDR3 of two different SS patients matched CDR3 with specificity for Influenza and Epstein-Barr viruses. Besides detecting clonality, these findings shed light on the nature of SS-related antigens, pointing to RNA sequencing as a useful tool for simultaneous clonality and biological analysis in SS. We performed RNA sequencing of TR alpha (TRA) and beta (TRB) in peripheral blood CD4 + T cells from Sezary Syndrome (SS) and psoriasis patients (PS) employed as controls and found correlated (A) and highly expanded predominant TRA and TRB complementarity-determining regions 3 (CDR3) only in SS patients (B). CDR3 almost identical to the predominant were identified within each SS patient and were exponentially correlated with frequencies of the predominant CDR3 (C), and shared CDR3 (D) enriched in antigen matches between different patients (including CMV, Epstein-Barr virus, Influenza virus and self-antigens) were also detected (E). Besides detecting clonality, these findings shed light on the nature of SS-related antigens, pointing to RNA sequencing as a useful tool for simultaneous clonality and biological analysis in SS.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Genetics Abnormalities with Clinical Impact in Primary Cutaneous Lymphomas

  • Gallardo, Fernando|||0000-0002-8996-3828
  • Pujol Vallverdú, Ramón M|||0000-0002-5622-6055
Primary cutaneous lymphomas comprise a heterogeneous group of extranodal non-Hodgkin lymphomas (NHL) that arise from skin resident lymphoid cells and are manifested by specific lymphomatous cutaneous lesions with no evidence of extracutaneous disease at the time of diagnosis. They may originate from mature T-lymphocytes (70% of all cases), mature B-lymphocytes (25-30%) or, rarely, NK cells. Cutaneous T-cell lymphomas (CTCL) comprise a heterogeneous group of T-cell malignancies including Mycosis Fungoides (MF) the most frequent subtype, accounting for approximately half of CTCL, and Sézary syndrome (SS), which is an erythrodermic and leukemic subtype characterized by significant blood involvement. The mutational landscape of MF and SS by NGS include recurrent genomic alterations in the TCR signaling effectors (i.e., PLCG1), the NF-κB elements (i.e., CARD11), DNA damage/repair elements (TP53 or ATM), JAK/STAT pathway elements or epigenetic modifiers (DNMT3). Genomic copy number variations appeared to be more prevalent than somatic mutations. Other CTCL subtypes such as primary cutaneous anaplastic large cell lymphoma also harbor genetic alterations of the JAK/STAT pathway in up to 50% of cases. Recently, primary cutaneous aggressive epidermotropic T-cell lymphoma, a rare fatal subtype, was found to contain a specific profile of JAK2 rearrangements. Other aggressive cytotoxic CTCL (primary cutaneous γδ T-cell lymphomas) also show genetic alterations in the JAK/STAT pathway in a large proportion of patients. Thus, CTCL patients have a heterogeneous genetic/transcriptional and epigenetic background, and there is no uniform treatment for these patients. In this scenario, a pathway-based personalized management is required. Cutaneous B-cell lymphoma (CBCL) subtypes present a variable genetic profile. The genetic heterogeneity parallels the multiple types of specialized B-cells and their specific tissue distribution. Particularly, many recurrent hotspot and damaging mutations in primary cutaneous diffuse large B-cell lymphoma of the leg type, involving MYD88 gene, or BCL6 and MYC translocations and BLIMP1 or CDKN2A deletions are useful for diagnostic and prognostic purposes for this aggressive subtype from other indolent CBCL forms.